Adrenergic Uptake Inhibitors
"Adrenergic Uptake Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
| Descriptor ID |
D018759
|
| MeSH Number(s) |
D27.505.519.562.437.050 D27.505.519.625.050.601 D27.505.519.625.600.050 D27.505.696.577.050.601 D27.505.696.577.600.050
|
| Concept/Terms |
Adrenergic Uptake Inhibitors- Adrenergic Uptake Inhibitors
- Inhibitors, Adrenergic Reuptake
- Reuptake Inhibitors, Adrenergic
- Uptake Inhibitors, Adrenergic
- Adrenergic Reuptake Inhibitors
- Inhibitors, Adrenergic Uptake
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic Uptake Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic Uptake Inhibitors".
This graph shows the total number of publications written about "Adrenergic Uptake Inhibitors" by people in this website by year, and whether "Adrenergic Uptake Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 3 | 4 |
| 2010 | 2 | 2 | 4 |
| 2012 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic Uptake Inhibitors" by people in Profiles.
-
Wang Z, Zuschlag ZD, Myers US, Hamner M. Atomoxetine in comorbid ADHD/PTSD: A randomized, placebo controlled, pilot, and feasibility study. Depress Anxiety. 2022 04; 39(4):286-295.
-
Turner TH, Renfroe JB, Elm J, Duppstadt-Delambo A, Hinson VK. Robustness of reliable change indices to variability in Parkinson's disease with mild cognitive impairment. Appl Neuropsychol Adult. 2016 Nov-Dec; 23(6):399-402.
-
Arias HR, Fedorov NB, Benson LC, Lippiello PM, Gatto GJ, Feuerbach D, Ortells MO. Functional and structural interaction of (-)-reboxetine with the human a4ß2 nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 2013 Jan; 344(1):113-23.
-
McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict. 2010 Nov-Dec; 19(6):481-9.
-
Annamalai B, Mannangatti P, Arapulisamy O, Ramamoorthy S, Jayanthi LD. Involvement of threonine 258 and serine 259 motif in amphetamine-induced norepinephrine transporter endocytosis. J Neurochem. 2010 Oct; 115(1):23-35.
-
Buchanan HA, Daéid NN, Kerr WJ, Carter JF, Hill JC. Role of five synthetic reaction conditions on the stable isotopic composition of 3,4-methylenedioxymethamphetamine. Anal Chem. 2010 Jul 01; 82(13):5484-9.
-
Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD, Kugler JW, Hoff KL, Reddy PS, Rowland KM, Riepl M, Christensen B, Loprinzi CL. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011 Jun; 19(6):833-41.
-
Bundy DG, Rinke ML, Shore AD, Hicks RW, Morlock LL, Miller MR. Medication errors in the ambulatory treatment of pediatric attention deficit hyperactivity disorder. Jt Comm J Qual Patient Saf. 2008 Sep; 34(9):552-9, 497.
-
Saylor AJ, McGinty JF. Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice. Genes Brain Behav. 2008 Nov; 7(8):906-14.
-
Clark C, DeLegge M. Irritable bowel syndrome: a practical approach. Nutr Clin Pract. 2008 Jun-Jul; 23(3):263-7.